Cotización Synthetic Biologics - SYN

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

1.02

Postura de Compra

Postura de Venta

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

17.384M

Precio Anterior

1.02

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

17,043,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-1.21

Beneficio por acción (BPA)

-1.08

turnover

Beneficio neto

-18.35M

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbio... Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Business Services

Sitio web

www.syntheticbiologics.com

Sede

Rockville, Maryland, USA

Fundado

1993

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire ROCKVILLE, Md., Feb. 9, 2022 ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE...

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned acquisition of VCN Biosciences...

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire ROCKVILLE, Md., Jan. 26, 2022 ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic...

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate...

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical...

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET...

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 2022 Phase 1 Clinical...

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by...

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire ROCKVILLE, Md., Sept. 21, 2021 ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/...

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
ATNMActinium Pharmaceuticals Inc	US$ 1.57 (17.16%)	40
MINFT Limited	US$ 4.92 (13.44%)	1.93k
SLNDSouthland Holdings Inc	US$ 3.39 (11.15%)	7.27k
UAMYUnited States Antimony Corp	US$ 1.09 (11.12%)	159.6k
TMPTompkins Financial Corporation	US$ 84.00 (10.47%)	235
XTREBondbloxx Bloomberg 3 Year Target Duration Us Treasury ETF	US$ 43.31 (-11.56%)	11
SOARVolato Group Inc	US$ 0.3276 (-10.49%)	720.58k
BHBBar Harbor Bankshares	US$ 32.65 (-7.98%)	7
ETHDProshares Ultrashort Ether ETF	US$ 19.49 (-7.67%)	13.49k
ATCHAtlasClear Holdings Inc	US$ 0.198 (-6.43%)	120.83k
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 1.06 (-4.07%)	9.4M
CANFCan Fite BioPharma Ltd	US$ 2.07 (4.02%)	6.36M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 31.24 (5.08%)	1.99M
ETHU2x Ether ETF	US$ 10.44 (6.31%)	1.84M
OPTTOcean Power Technologies Inc	US$ 0.3539 (-4.35%)	1.06M